These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 35431912)

  • 1. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
    Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
    [No Abstract]   [Full Text] [Related]  

  • 2. The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder.
    Levin AW; Lancelotta R; Sepeda ND; Gukasyan N; Nayak S; Wagener TL; Barrett FS; Griffiths RR; Davis AK
    PLoS One; 2024; 19(3):e0300501. PubMed ID: 38483940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
    Roseman L; Nutt DJ; Carhart-Harris RL
    Front Pharmacol; 2017; 8():974. PubMed ID: 29387009
    [No Abstract]   [Full Text] [Related]  

  • 4. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.
    Watts R; Kettner H; Geerts D; Gandy S; Kartner L; Mertens L; Timmermann C; Nour MM; Kaelen M; Nutt D; Carhart-Harris R; Roseman L
    Psychopharmacology (Berl); 2022 Nov; 239(11):3461-3483. PubMed ID: 35939083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
    Nygart VA; Pommerencke LM; Haijen E; Kettner H; Kaelen M; Mortensen EL; Nutt DJ; Carhart-Harris RL; Erritzoe D
    J Psychopharmacol; 2022 Aug; 36(8):932-942. PubMed ID: 35924888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.
    Calder AE; Rausch B; Liechti ME; Holze F; Hasler G
    J Psychopharmacol; 2024 Oct; 38(10):873-886. PubMed ID: 39302087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder.
    Heinzerling KG; Sergi K; Linton M; Rich R; Youssef B; Bentancourt I; Bramen J; Siddarth P; Schwartzberg L; Kelly DF
    Front Psychiatry; 2023; 14():1215972. PubMed ID: 37795513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.
    Barrett FS; Robbins H; Smooke D; Brown JL; Griffiths RR
    Front Psychol; 2017; 8():1238. PubMed ID: 28790944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis.
    Ko K; Carter B; Cleare AJ; Rucker JJ
    Neuropsychiatr Dis Treat; 2023; 19():2105-2113. PubMed ID: 37818448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.
    Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME
    J Psychopharmacol; 2024 Jan; 38(1):80-100. PubMed ID: 37905369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body mass index (BMI) does not predict responses to psilocybin.
    Spriggs MJ; Giribaldi B; Lyons T; Rosas FE; Kärtner LS; Buchborn T; Douglass HM; Roseman L; Timmermann C; Erritzoe D; Nutt DJ; Carhart-Harris RL
    J Psychopharmacol; 2023 Jan; 37(1):107-116. PubMed ID: 36373934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
    Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
    J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.
    Szigeti B; Weiss B; Rosas FE; Erritzoe D; Nutt D; Carhart-Harris R
    Psychol Med; 2024 Jun; 54(8):1717-1724. PubMed ID: 38247730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.
    Erritzoe D; Barba T; Spriggs MJ; Rosas FE; Nutt DJ; Carhart-Harris R
    J Psychopharmacol; 2024 May; 38(5):458-470. PubMed ID: 38520045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.
    Nayak SM; Bari BA; Yaden DB; Spriggs MJ; Rosas FE; Peill JM; Giribaldi B; Erritzoe D; Nutt DJ; Carhart-Harris R
    Psychedelic Med (New Rochelle); 2023 Mar; 1(1):18-26. PubMed ID: 37337526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy.
    Sekula AD; Downey L; Puspanathan P
    Front Psychol; 2022; 13():813746. PubMed ID: 35310225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.